BeStock  
Stocks › Biotechnology › NRIX

Nurix Therapeutics NRIX

US equityMarket cap rank #2921Biotechnology
$12.85 −$0.75 (-5.51%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $12.85 0.00%
Open$13.40
Prev close$13.60
Day range$12.83 – $13.67
Volume2.43M
Market cap$1.40B
P/E (TTM)5.3
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings6.4x
CheapRich

Near the top of its 5-year range · 98th percentile, 5-year average -4.9x

#290 of 2993 stocks by PE (1 = cheapest)

Price / book1.7x
CheapRich

Below its usual level · 29th percentile, 5-year average 2.9x

#2799 of 5330 stocks by PB (1 = cheapest)

Price / sales2.4x
CheapRich

Near the bottom of its 5-year range · 0th percentile, 5-year average 19.6x

#2803 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-22x-10x2x14xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$16.66
Price vs. fair value-22.9%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyHigh
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 1.75 – 2.91 29% (cheaper than usual) #2799 of 5330 (1 = cheapest)
PE 6.37 -76.16 -4.94 98% (pricier than usual) #290 of 2993 (1 = cheapest)
PS 2.41 5.08 19.57 0% (cheaper than usual) #2803 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on NRIX.

Sign in to join the discussion.

Scroll to Top